Little Impact of Antiplatelet Agents on Venous Thromboembolism after Hip Fracture Surgery.
10.3346/jkms.2011.26.12.1625
- Author:
Hyung Min JI
1
;
Young Kyun LEE
;
Yong Chan HA
;
Ki Choul KIM
;
Kyung Hoi KOO
Author Information
1. Department of Orthopaedic Surgery, Ajou University School of Medicine, Suwon, Korea.
- Publication Type:Original Article
- Keywords:
Venous Thromboembolism;
Venous Thrombosis;
Pulmonary Embolism;
Incidence;
Hip Fractures;
Antiplatelet Agents
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Anticoagulants/therapeutic use;
Aspirin/administration & dosage/pharmacology/*therapeutic use;
Female;
Hip Fractures/complications/*surgery;
Humans;
Male;
Middle Aged;
Multivariate Analysis;
Platelet Aggregation Inhibitors/*therapeutic use;
Postoperative Complications/drug therapy/*epidemiology/*prevention & control;
Regression Analysis;
Venous Thromboembolism/complications/*epidemiology/*prevention & control
- From:Journal of Korean Medical Science
2011;26(12):1625-1629
- CountryRepublic of Korea
- Language:English
-
Abstract:
Since the late 1980s, low dose aspirin has been used to prevent stroke and ischemic heart disease. However, prophylactic effect of antiplatelets against venous thromboembolism (VTE), in patients who undergo hip fracture surgery (HFS) is controversial. Our purpose was to determine the incidence of symptomatic VTE after HFS and to evaluate whether antiplatelets reduce the development of symptomatic VTE following HFS. We retrospectively reviewed 858 HFS in 824 consecutive patients which were performed from May 2003 to April 2010 at an East Asian institute. We compared the incidence of symptomatic VTE in antiplatelet users and non-users using multivariate logistic regression analyses. Overall incidences of symptomatic pulmonary embolism including fatal pulmonary embolism, and symptomatic deep vein thrombosis in this study were 2.4% (21/858), and 3.5% (30/858), respectively. The incidence of symptomatic VTE was 4.8% (12/250) in antiplatelet users and 4.3% (26/608) in non-users (P = 0.718). It is suggested that antiplatelet agents are not effective in prevention of symptomatic VTE after HFS.
